Correlation Between Oncolytics Biotech and Inhibikase Therapeutics

Can any of the company-specific risk be diversified away by investing in both Oncolytics Biotech and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncolytics Biotech and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oncolytics Biotech and Inhibikase Therapeutics, you can compare the effects of market volatilities on Oncolytics Biotech and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncolytics Biotech with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncolytics Biotech and Inhibikase Therapeutics.

Diversification Opportunities for Oncolytics Biotech and Inhibikase Therapeutics

0.33

Correlation Coefficient

Oncolytics Biotech  Inhibikase Therapeutics

Weak diversification

The 3 months correlation between Oncolytics and Inhibikase is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Oncolytics Biotech and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and Oncolytics Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncolytics Biotech are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of Oncolytics Biotech i.e., Oncolytics Biotech and Inhibikase Therapeutics go up and down completely randomly.

Pair Corralation between Oncolytics Biotech and Inhibikase Therapeutics

Given the investment horizon of 90 days Oncolytics Biotech is expected to under-perform the Inhibikase Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Oncolytics Biotech is 1.71 times less risky than Inhibikase Therapeutics. The stock trades about -0.09 of its potential returns per unit of risk. The Inhibikase Therapeutics is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  276.00  in Inhibikase Therapeutics on December 2, 2024 and sell it today you would lose (46.00) from holding Inhibikase Therapeutics or give up 16.67% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Oncolytics Biotech  vs.  Inhibikase Therapeutics

Oncolytics Biotech

Risk-Adjusted Performance

Very Weak

Over the last 90 days Oncolytics Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Inhibikase Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Inhibikase Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable forward-looking signals, Inhibikase Therapeutics is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Oncolytics Biotech and Inhibikase Therapeutics

The main advantage of trading using opposite Oncolytics Biotech and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncolytics Biotech position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.

The idea behind Oncolytics Biotech and Inhibikase Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.